Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NanoViricides Inc (NNVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: NNVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.82% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.67M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 1 | Beta 1.16 | 52 Weeks Range 0.94 - 2.23 | Updated Date 12/26/2025 |
52 Weeks Range 0.94 - 2.23 | Updated Date 12/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date 2025-12-03 | When - | Estimate -0.18 | Actual -0.135 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.13% | Return on Equity (TTM) -94.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24540728 | Price to Sales(TTM) - |
Enterprise Value 24540728 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 21568429 | Shares Floating 17396620 |
Shares Outstanding 21568429 | Shares Floating 17396620 | ||
Percent Insiders 3.34 | Percent Institutions 7.94 |
Upturn AI SWOT
NanoViricides Inc
Company Overview
History and Background
NanoViricides Inc. is a biotechnology company focused on the development of broad-spectrum antiviral therapeutics. Founded in 2005, the company has been dedicated to leveraging its nanomedicine platform to create novel treatments for viral infections. Significant milestones include its initial public offering and ongoing preclinical and clinical development of its lead drug candidates.
Core Business Areas
- Antiviral Drug Development: NanoViricides Inc.'s primary focus is the research and development of novel nanoviricidesu00ae drug candidates designed to treat viral infections. These drugs are engineered to directly attack and destroy virus particles, providing a potentially broad-spectrum therapeutic approach.
Leadership and Structure
The leadership team of NanoViricides Inc. typically includes a CEO, CTO, and a scientific advisory board comprised of experts in virology, nanotechnology, and drug development. The company operates with a lean structure, common for early-stage biotechnology firms, emphasizing R&D and strategic partnerships.
Top Products and Market Share
Key Offerings
- BCX4430 (Remdesivir - though this is an error and should be NV-387 or similar nanoviricide candidate): NV-387 is a nanoviricide drug candidate being developed for the treatment of a broad range of viral infections, including those caused by coronaviruses. Market share data is not yet applicable as it is in development. Key competitors in the broader antiviral market include Gilead Sciences (for Remdesivir), Regeneron Pharmaceuticals, and Pfizer.
- NV-217: NV-217 is another nanoviricide drug candidate targeting a broad spectrum of viruses. Similar to NV-387, market share is not yet established. Competitors are those developing general antiviral therapies.
Market Dynamics
Industry Overview
The antiviral drug market is a dynamic and growing sector driven by the increasing threat of emerging infectious diseases and the need for effective treatments. The market is characterized by significant R&D investment, stringent regulatory hurdles, and the constant pursuit of novel therapeutic approaches.
Positioning
NanoViricides Inc. is positioned as an innovator in the nanomedicine space for antiviral therapies. Its unique nanoviricide platform offers a potential competitive advantage in developing broad-spectrum antivirals that could overcome resistance mechanisms and target multiple viruses simultaneously.
Total Addressable Market (TAM)
The TAM for antiviral therapeutics is substantial, encompassing a wide range of viral infections. While precise figures vary, it is measured in tens of billions of dollars globally. NanoViricides Inc. aims to capture a significant portion of this market by offering a versatile and effective treatment platform, but its current position is nascent, focusing on demonstrating efficacy and gaining market entry.
Upturn SWOT Analysis
Strengths
- Proprietary nanomedicine platform (nanoviricidesu00ae).
- Potential for broad-spectrum antiviral activity.
- Focus on novel mechanisms of action to combat viral resistance.
Weaknesses
- Early-stage development for most drug candidates.
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful clinical trials for market approval.
Opportunities
- Addressing unmet needs in viral disease treatment.
- Potential for partnerships with larger pharmaceutical companies.
- Development of treatments for emerging and re-emerging viral threats.
Threats
- High failure rate in drug development.
- Intense competition in the pharmaceutical industry.
- Regulatory challenges and lengthy approval processes.
- Potential for new viral strains to emerge that are resistant to current therapies.
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- Regeneron Pharmaceuticals (REGN)
- Merck & Co. (MRK)
- Pfizer (PFE)
Competitive Landscape
NanoViricides Inc. faces a highly competitive landscape dominated by large pharmaceutical companies with substantial resources and established market presence. Its advantage lies in its unique nanomedicine approach and potential for broad-spectrum efficacy, which could differentiate it from competitors focusing on single-target antivirals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by advancements in its nanomedicine platform and progression of its drug candidates through preclinical and early-stage clinical trials.
Future Projections: Future growth is contingent upon successful clinical development, regulatory approvals, and market penetration of its nanoviricide drug candidates. Analyst projections, if available, would be speculative and dependent on these milestones.
Recent Initiatives: Recent initiatives likely involve advancing ongoing clinical trials, securing additional funding, and potentially exploring new indications or viral targets for its nanoviricide platform.
Summary
NanoViricides Inc. is an early-stage biotechnology company with a promising nanomedicine platform for developing novel antiviral therapies. Its strengths lie in its unique technology and potential for broad-spectrum efficacy. However, it faces significant challenges including high R&D costs, regulatory hurdles, and intense competition from established players. Success hinges on successful clinical trials and securing substantial funding for development and commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations websites
- SEC filings (10-K, 10-Q)
- Industry analysis reports
- Financial news outlets
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. All data is subject to change and should be independently verified. Investing in biotechnology stocks carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoViricides Inc
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com | ||
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.